|Bid||150.00 x 1100|
|Ask||160.00 x 800|
|Day's Range||155.76 - 160.28|
|52 Week Range||125.50 - 178.15|
|PE Ratio (TTM)||180.08|
|Earnings Date||Jul 24, 2018 - Jul 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||191.45|
Vertex Pharmaceuticals Incorporated today announced that Senior Vice President Paul Negulescu has been named one of the winners of this year’s Warren Alpert Foundation Prize for “transformative discoveries in the fields of genetics, physiology, pulmonology and pharmacology that led to the development of life-altering precision-targeted treatments for the devastating multi-organ disease cystic fibrosis ...
Trading well below their one-year highs, big biotech stocks look set for a rebound as their fundamentals are showing signs of improvement. More stable product pricing environments, earnings improvement and successful new drug trials, are just a few of the factors that could lead to a biotech rally in the second half of the year, with firms like Gilead Sciences Inc. ( GILD), Alexion Pharmaceuticals Inc. ( ALXN) and Vertex Pharmaceuticals Inc. ( VRTX) leading the charge.
On June 19, Solid Biosciences’ (SLDB) stock price rose ~46.6% to $43.00. On June 19, Solid Biosciences’ stock price hit a 52-week high of $54.84.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the opening of its new 170,000 square foot research facility in Torrey Pines, San Diego. The San Diego site is one of Vertex’s three global research hubs, and is where the Company’s three breakthrough cystic fibrosis (CF) medicines were discovered. “Our researchers in San Diego have spent the last 20 years doing what was once thought impossible – developing the first medicines that treat the underlying cause of cystic fibrosis,” said Dr. David Altshuler, Executive Vice President, Global Research and Chief Scientific Officer.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that ORKAMBI® (lumacaftor/ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF) in people with two copies of the F508del mutation, ages six and older, will be reimbursed in Sweden after concluding the three-party negotiations with TLV and the county councils. “We are delighted that people with CF in Sweden will join the thousands of others around the world who are already benefitting from our CF medicines,” said Simon Bedson, International General Manager at Vertex.
Earlier this year, Oppenheimer's Hartaj Singh argued that earnings expectations were too high for big biotech companies heading into the first-quarter reporting season. Ahead of the reports, due out in mid-July, Singh argues that fundamentals for large-cap biotech, as well as sector sentiment are "slowly but surely improving," leading him to believe that the stocks could outperform, led by Gilead Sciences (GILD), Alexion Pharmaceuticals (ALXN), and Vertex Pharmaceuticals (VRTX). For Gilead, he's upbeat about a more stable pricing environment for hepatitis C treatments, while investors are getting more interested in the company's "budding" immunology and nonalcoholic steatohepatitis (NASH) franchises, setting up an attractive risk-reward profile going into the second quarter. Alexion reported "stellar" first-quarter earnings, and Singh sees another strong quarter ahead, and he wonders "when the Street will start giving management credit for relentless execution." Vertex is one of his favorite large-cap biotechs, and he sees a good report ahead, along with an update about the progress of its cystic-fibrosis drugs.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that Vertex employees and The Vertex Foundation have together donated over $1 million through the Company’s new dollar-for-dollar matching gift program. The funds demonstrate the Company’s long-term commitment to giving back and to supporting employees’ deep commitment to strengthening their communities. The matching gift program launched on November 28, 2017 and was created to extend the impact of employee donations to qualified nonprofit organizations.
Ten years ago, drug hunter Mark Murcko was thinking about motion. Then the chief technology officer of Vertex Pharmaceuticals Inc., Murcko was a pioneer. Unraveling how diseased proteins are constructed made Vertex, founded in 1989, into one of the largest biotechnology companies in the world.
Vertex is getting some breathing room, an analyst said Thursday, as rival Proteostasis tumbled on disappointing results from a study of its cystic fibrosis drug.
Vertex Pharmaceuticals Incorporated (VRTX) today announced 10 scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 41st European Cystic Fibrosis Conference taking place June 6-9, 2018, in Belgrade, Serbia. Collectively, the data support the potential disease-modifying benefits of treating the underlying cause of CF and Vertex’s progress toward enhancing and expanding treatment options for all people living with CF. Data from the ongoing Phase 3, open-label ARRIVAL study presented at an oral session and published online today in The Lancet Respiratory Medicine show that treatment with KALYDECO® (ivacaftor) resulted in substantial decreases in mean sweat chloride as well as improvements to multiple efficacy endpoints, suggesting the potential to preserve pancreatic function and modify the course of CF beginning in children as young as one year of age.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that management will present at the Goldman Sachs Healthcare Conference on Wednesday, June 13, 2018 at 5:40 p.m. ET (2:40 p.m. PT). The audio portion of management’s remarks will be available live through Vertex’s website, www.vrtx.com in the “Investors” section under the “News and Events” page. A replay of the conference webcast will be archived on the company’s website.
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
When Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its most recent earnings (31 March 2018), I did two things: looked at its past earnings track record, then look at what is happeningRead More...
LONDON, UK / ACCESSWIRE / June 5, 2018 / If you want a free Stock Review on VSAR sign up now at www.wallstequities.com/registration. This Tuesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Versartis Inc. (NASDAQ: VSAR), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), 22nd Century Group Inc. (NYSE AMER: XXII), and Abeona Therapeutics Inc. (NASDAQ: ABEO).
Don't worry about the FDA's clinical hold on gene-editing therapy CTX001. Vertex and CRISPR Therapeutics stocks will bounce back.
Quite often in stock markets, companies that offer something novel and unique attract speculators. CRSP stock has two positive catalysts at this time. Fundamentally, the company’s high valuation could limit any more near-term upside, though.
The FDA placed a clinical hold on the Investigational New Drug application for Crispr's CTX001 for the treatment of sickle cell disease, Crispr and its partner Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) said in a press release. The details of the FDA's hold are not revealed to the market, so the overall implications for Crispr aren't fully known, Chardan's Gbola Amusa said in a research report. Crispr and Vertex expect to receive additional information on the FDA's list of questions in the "near future" and will "work rapidly" with the FDA toward a solution, the press release said.
The story of how Vertex went from being a potential also-ran to a local giant with $2 billion in annual revenue and 2,300 employees offers some lessons on how to stand out in this increasingly crowded and competitive sector.
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.